Jie-er Ying

Zhejiang Key Laboratory Of Prevention
Hangzhou, 310022, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

SMOC2 promotes peritoneal metastasis of gastric cancer involving Wnt/β-catenin pathway modulation and inducing angiogenesis.

SMOC2 promotes peritoneal metastasis of gastric cancer involving Wnt/β-catenin pathway modulation and inducing angiogenesis.

Journal: Clinical and experimental medicine

Published: August 05, 2025

Safety and preliminary efficacy results of IBI389, an anti-Claudin18.2×CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: a phase 1 dose escalation and expansion study.

Safety and preliminary efficacy results of IBI389, an anti-Claudin18.2×CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: a phase 1 dose escalation and expansion study.

Journal: BMC medicine

Published: July 30, 2025

Metabolic dysfunction-associated steatotic liver disease accelerates pancreatic cancer progression and metastasis via the macrophage migration inhibitory factor-CD44 axis.

Metabolic dysfunction-associated steatotic liver disease accelerates pancreatic cancer progression and metastasis via the macrophage migration inhibitory factor-CD44 axis.

Journal: Signal transduction and targeted therapy

Published: June 03, 2025

DLAT activates EMT to promote HCC metastasis by regulating GLUT1-mediated aerobic glycolysis.

DLAT activates EMT to promote HCC metastasis by regulating GLUT1-mediated aerobic glycolysis.

Journal: Molecular medicine (Cambridge, Mass.)

Published: October 12, 2024

Multi-omics analysis uncovers predictive biomarkers for the efficacy and outcomes of chemoimmunotherapy in advanced unresectable biliary tract cancers.

Multi-omics analysis uncovers predictive biomarkers for the efficacy and outcomes of chemoimmunotherapy in advanced unresectable biliary tract cancers.

Journal: BMC medicine

Published: September 28, 2024

Sintilimab and anlotinib with gemcitabine plus cisplatin in advanced biliary tract cancer: SAGC a randomized phase 2 trial.

Sintilimab and anlotinib with gemcitabine plus cisplatin in advanced biliary tract cancer: SAGC a randomized phase 2 trial.

Journal: Nature communications

Published: June 10, 2024

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023.

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023.

Journal: Cancer communications (London, England)

Published: December 08, 2023

Potential mechanisms and targeting strategies of the gut microbiota in antitumor immunity and immunotherapy.

Potential mechanisms and targeting strategies of the gut microbiota in antitumor immunity and immunotherapy.

Journal: Immunity, inflammation and disease

Published: September 20, 2023

The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors.

The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors.

Journal: Journal of hematology & oncology

Published: September 06, 2023

Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy.

Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: July 13, 2023

Performance evaluation of a CRISPR Cas9-based selective exponential amplification assay for the detection of KRAS mutations in plasma of patients with advanced pancreatic cancer.

Performance evaluation of a CRISPR Cas9-based selective exponential amplification assay for the detection of KRAS mutations in plasma of patients with advanced pancreatic cancer.

Journal: Journal of clinical pathology

Published: May 22, 2023

Development of potent antibody drug conjugates against ICAM1+ cancer cells in preclinical models of cholangiocarcinoma.

Development of potent antibody drug conjugates against ICAM1+ cancer cells in preclinical models of cholangiocarcinoma.

Journal: NPJ precision oncology

Published: February 05, 2023

Showing 1-12 of 23

Last Updated: 09/26/2026